Drug Patents owned by Aaa Usa Novartis
1. List of Locametz drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US11369590 | AAA USA NOVARTIS | PSMA binding ligand-linker conjugates and methods for using |
Aug, 2028
(5 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Product (NP) | Mar 23, 2025 |
Drugs and Companies using GALLIUM GA-68 GOZETOTIDE ingredient
Market Authorisation Date: 23 March, 2022
Treatment: For use after radiolabeling with gallium-68, for positron emission tomography of prostate-specific membrane antigen (psma)-positive lesions in men with prostate cancer
Dosage: POWDER;INTRAVENOUS
LOCAMETZ family patents
26
United States
8
Japan
6
European Union
2
New Zealand
2
China
1
Portugal
1
Hungary
1
Slovenia
1
Hong Kong
1
Israel
1
Poland
1
Australia
1
Denmark
1
Spain
1
Canada
2. List of Pluvicto drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US11318121 | AAA USA NOVARTIS | PSMA binding ligand-linker conjugates and methods for using |
Aug, 2028
(5 years from now) | |
| US10406240 | AAA USA NOVARTIS | PSMA binding ligand-linker conjugates and methods for using |
Aug, 2028
(5 years from now) | |
| US10398791 | AAA USA NOVARTIS | Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer |
Oct, 2034
(11 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Mar 23, 2027 |
Drugs and Companies using LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN ingredient
NCE-1 date: 2026-03-23
Market Authorisation Date: 23 March, 2022
Treatment: For treatment of adult patients with prostate-specific membrane antigen (psma)-positive metastatic castration-resistant prostate cancer (mcrpc) who have been treated with androgen receptor (ar) pathway inhibition and taxane-based chemotherapy
Dosage: SOLUTION;INTRAVENOUS
PLUVICTO family patents
33
United States
14
Japan
14
European Union
4
China
4
Australia
3
New Zealand
3
Korea, Republic of
3
Israel
2
Peru
2
Hong Kong
2
South Africa
2
Canada
1
Portugal
1
Singapore
1
Spain
1
Philippines
1
Mexico
1
Morocco
1
EA
1
Tunisia
1
Slovenia
1
Saudi Arabia
1
Hungary
1
Poland
1
Georgia
1
Chile
1
Denmark
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic